Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

NIMH

Drug and asset intelligence for NIMH with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
2
Stage
Development stage unavailable

Recent signals(5)

ClinicalJuly 17, 2026

NIMH Initiates PET Imaging Study with New Tracer 11C-ARMI for Brain Research

The National Institute of Mental Health is testing a new radioactive tracer, 11C-ARMI, in healthy individuals to evaluate its effectiveness in imaging brain function.

ClinicalJuly 11, 2026

NIMH Study on Adolescent Depression Aims to Enhance Treatment Understanding

The NIMH is conducting a study to explore causes and treatments for depression in adolescents aged 11-17, comparing those with and without mental health diagnoses.

ClinicalJuly 4, 2026

NIMH Study on MRI and MRS Techniques for Brain Chemistry Imaging

The National Institute of Mental Health is developing and optimizing MRI and MRS techniques to study brain chemistry.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— NIMH

July 11, 2026 · N/A

Topline Data

— NIMH

June 19, 2026 · N/A

Indications

Pediatric Bipolar Disorder →

Therapeutic areas

Depression →
Imaging →
Imaging Techniques →
Mental Health →
Mental Health · Depression →
Neurology →
Neuroscience →
Pediatric Bipolar Disorder →
Psychiatry →
Psychiatry · Pediatric Bipolar Disorder →
Schizophrenia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

ClinicalJuly 1, 2026

NIMH Launches Genetic Study to Understand Schizophrenia Neurobiology

The National Institute of Mental Health is conducting a large study to identify susceptibility genes related to schizophrenia.

ClinicalJune 19, 2026

NIMH Study on Brain Function in Pediatric Bipolar Disorder

The NIMH is conducting a study to investigate severe mood dysregulation in children aged 7-17, focusing on symptoms and brain changes.